4 results
To compare the number of responders to vaccination with pneumococcal and conjugated Hib vaccine at different time points after last dose of rituximab, to investigate what the ideal moment of vaccination would be. Secondly to study the immune-…
To investigate what the ideal moment to vaccinate would be, early (after 2-6 months) or late (after 9-12 months) after cessation of rituximab. Secondly to study the immune-response to vaccination with influenza virus vaccine after treatment with…
The objectives of this extension trial are to assess the long-term safety and maintenance of efficacy beyond 2 to 2.5 years of treatment with glepaglutide in adult patients with SBS.Primary Objective:To evaluate the long-term safety of glepaglutide…
This study will evaluate the efficacy and safety of multiple therapies that are selected using somatic alterations and potential predictive biomarkers identified via NGS assays in patients with solid tumors: